{"url":"https://nivawealth.com/firms/acuta-capital-partners-158869","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/158869","regulatoryAum":172526516,"crd":"158869","history":[{"filedOn":"2021-03-30","regulatoryAum":602999190,"clients":3,"employees":7,"offices":1},{"filedOn":"2022-03-31","regulatoryAum":405090270,"clients":3,"employees":7,"offices":1},{"filedOn":"2023-03-31","regulatoryAum":279460422,"clients":3,"employees":6,"offices":1},{"filedOn":"2024-03-27","regulatoryAum":244228617,"clients":3,"employees":6,"offices":1},{"filedOn":"2026-06-30","regulatoryAum":172526516,"clients":3,"employees":4,"offices":1}],"secFileNumber":"801-136966","legalName":"Acuta Capital Partners, LLC","displayName":"Acuta Capital Partners","slug":"acuta-capital-partners-158869","website":"https://acutacapital.com/","logo":{"src":"https://rmkhnxnbeclogprvkfyl.supabase.co/storage/v1/object/public/firm-logos/158869/c8989ca74f7562ca-r1.webp","tone":"light","width":559,"height":200,"sourceUrl":"https://www.acutacapital.com","sourceLabel":"Acuta Capital Partners, LLC, website"},"classification":{"segment":"private_funds","segmentLabel":"Private funds","type":"private_fund_manager","typeLabel":null,"feeDisclosure":"payment_only"},"linkedinUrl":"https://www.linkedin.com/company/acuta-capital-partners-llc","founded":null,"organization":"Delaware limited liability company","fiscalYearEnd":"December","headquarters":{"street":"255 Shoreline Drive, Suite 515","city":"Redwood City","state":"CA","stateName":"California","country":"United States","postalCode":"94065"},"tradeNames":[],"registration":{"secApproved":"9 September 2026","noticeFilings":null,"latestNoticeFiling":null},"wealthAumPerClient":null,"staff":{"employees":4,"advisory":3,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"regulatory":172526516,"discretionary":172526516,"discretionaryAccounts":3,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":33,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":3,"regulatoryAum":172526516}],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[],"custodyNote":"Acuta Capital Partners has custody of $157M for 2 clients.","otherCustodians":[],"leadership":[{"name":"Scott Smith","title":"Chief Operating Officer, Chief Compliance Officer","crd":"2943398"},{"name":"Anupam Dalal","title":"Managing Member, Chief Investment Officer","crd":"6038211"}],"ownership":[{"label":"Anupam Dalal","detail":"Managing member, chief investment officer in the 75% or more ownership band and a control person, since December 2017."},{"label":"The Lin-Lay Family 2007 Trust Dated September 7, 2007","detail":"Member in the 10% to 25% ownership band, since August 2018."},{"label":"Grace Lay","detail":"Indirect owner: beneficiary/trustee of The Lin-Lay Family 2007 Trust Dated September 7, 2007 and a control person, since August 2018.","parent":"The Lin-Lay Family 2007 Trust Dated September 7, 2007"},{"label":"Manfred Yu","detail":"Indirect owner: trustee of The Lin-Lay Family 2007 Trust Dated September 7, 2007 and a control person, since August 2018.","parent":"The Lin-Lay Family 2007 Trust Dated September 7, 2007"}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":0,"privateResidences":0},"listedOfficeAddresses":1,"foreignOffices":[],"officesByState":[{"state":"California","offices":1,"addresses":[{"street":"255 Shoreline Drive, Suite 515","city":"Redwood City","headquarters":true}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"650-486-0508","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":null,"assetMix":[],"privateFunds":2},"sources":{"adv1FilingDate":"30 June 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/158869/PDF/158869.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","updatedOn":"2026-10-21","holdingsUpdatedOn":"2026-10-21","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Acuta Capital Partners have?","answer":"Acuta Capital Partners has 3 clients and manages $173 million for them, as of June 2026. They include 3 pooled investment vehicles.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 30 June 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Acuta Capital Partners offer?","answer":"Acuta Capital Partners provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How many financial advisors does Acuta Capital Partners have?","answer":"Acuta Capital Partners has 0 investment adviser representatives registered with state securities authorities, out of 4 employees, and 3 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Acuta Capital Partners?","answer":"Acuta Capital Partners’ direct owners are Anupam Dalal (75% or more) and the Lin-Lay Family 2007 Trust Dated September 7, 2007 (10% to 25%).","source":"Form ADV Part 1A, Schedules A and B, filed 30 June 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Acuta Capital Partners get paid?","answer":"Acuta Capital Partners is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How do I contact Acuta Capital Partners?","answer":"Acuta Capital Partners’ main office is at 255 Shoreline Drive, Suite 515, Redwood City, CA 94065. Its phone number is 650-486-0508. Its website is acutacapital.com.","source":"Form ADV Part 1A, Item 1.F, filed 30 June 2026","sourceRef":{"doc":"adv1","section":"offices"}}],"holdings":{"url":"https://nivawealth.com/firms/acuta-capital-partners-158869/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-14","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1582844/000110465926096822/0001104659-26-096822-index.html","totalValue":143494671,"positionCount":23,"top10Share":0.7374701740666035,"top10":[{"issuer":"PRAXIS PRECISION MEDICINES I","titleOfClass":"COM NEW","cusip":"74006W207","value":27719273,"shares":82796,"shareType":"SH","priorValue":27354253,"priorShares":84901},{"issuer":"WHITEHAWK THERAPEUTICS INC","titleOfClass":"COM","cusip":"00032Q104","value":21461477,"shares":4685912,"shareType":"SH","priorValue":11765887,"priorShares":3410402},{"issuer":"TANGO THERAPEUTICS INC","titleOfClass":"COM","cusip":"87583X109","value":12221066,"shares":390949,"shareType":"SH","priorValue":9243105,"priorShares":441831},{"issuer":"SUTRO BIOPHARMA INC","titleOfClass":"COM","cusip":"869367201","value":8972333,"shares":270251,"shareType":"SH","priorValue":6711377,"priorShares":269425},{"issuer":"ARRIVENT BIOPHARMA INC","titleOfClass":"COM","cusip":"04272N102","value":7597430,"shares":218694,"shareType":"SH"},{"issuer":"4D MOLECULAR THERAPEUTICS INC","titleOfClass":"COM","cusip":"35104E100","value":6753753,"shares":507801,"shareType":"SH"},{"issuer":"BRIGHT MINDS BIOSCIENCES INC","titleOfClass":"COM NEW","cusip":"10919W405","value":6510699,"shares":92745,"shareType":"SH","priorValue":8172348,"priorShares":111996},{"issuer":"OCULAR THERAPEUTIX INC","titleOfClass":"COM","cusip":"67576A100","value":5228963,"shares":532481,"shareType":"SH","priorValue":5015155,"priorShares":592108},{"issuer":"ERASCA INC","titleOfClass":"COM","cusip":"29479A108","value":4858446,"shares":265199,"shareType":"SH","priorValue":5737024,"priorShares":354575},{"issuer":"SURROZEN INC","titleOfClass":"COM NEW","cusip":"86889P208","value":4499600,"shares":173395,"shareType":"SH","priorValue":5035033,"priorShares":172847}],"positionsListed":23,"positions":[{"issuer":"PRAXIS PRECISION MEDICINES I","titleOfClass":"COM NEW","cusip":"74006W207","value":27719273,"shares":82796,"shareType":"SH","priorValue":27354253,"priorShares":84901},{"issuer":"WHITEHAWK THERAPEUTICS INC","titleOfClass":"COM","cusip":"00032Q104","value":21461477,"shares":4685912,"shareType":"SH","priorValue":11765887,"priorShares":3410402},{"issuer":"TANGO THERAPEUTICS INC","titleOfClass":"COM","cusip":"87583X109","value":12221066,"shares":390949,"shareType":"SH","priorValue":9243105,"priorShares":441831},{"issuer":"SUTRO BIOPHARMA INC","titleOfClass":"COM","cusip":"869367201","value":8972333,"shares":270251,"shareType":"SH","priorValue":6711377,"priorShares":269425},{"issuer":"ARRIVENT BIOPHARMA INC","titleOfClass":"COM","cusip":"04272N102","value":7597430,"shares":218694,"shareType":"SH"},{"issuer":"4D MOLECULAR THERAPEUTICS INC","titleOfClass":"COM","cusip":"35104E100","value":6753753,"shares":507801,"shareType":"SH"},{"issuer":"BRIGHT MINDS BIOSCIENCES INC","titleOfClass":"COM NEW","cusip":"10919W405","value":6510699,"shares":92745,"shareType":"SH","priorValue":8172348,"priorShares":111996},{"issuer":"OCULAR THERAPEUTIX INC","titleOfClass":"COM","cusip":"67576A100","value":5228963,"shares":532481,"shareType":"SH","priorValue":5015155,"priorShares":592108},{"issuer":"ERASCA INC","titleOfClass":"COM","cusip":"29479A108","value":4858446,"shares":265199,"shareType":"SH","priorValue":5737024,"priorShares":354575},{"issuer":"SURROZEN INC","titleOfClass":"COM NEW","cusip":"86889P208","value":4499600,"shares":173395,"shareType":"SH","priorValue":5035033,"priorShares":172847},{"issuer":"ARGEN SE - ADR","titleOfClass":"SPONSORED ADR","cusip":"04016X101","value":4365158,"shares":4705,"shareType":"SH","priorValue":3424873,"priorShares":4690},{"issuer":"MOONLAKE IMMUNOTHERAPEUTICS","titleOfClass":"CLASS ORD A","cusip":"61559X104","value":4198744,"shares":215652,"shareType":"SH","priorValue":3574406,"priorShares":191760},{"issuer":"DESIGN THERAPEUTICS INC","titleOfClass":"COM","cusip":"25056L103","value":4088701,"shares":282564,"shareType":"SH","priorValue":1552376,"priorShares":145900},{"issuer":"MINERVA NEUROSCIENCES","titleOfClass":"COM NEW","cusip":"603380205","value":3937725,"shares":709500,"shareType":"SH","priorValue":4274738,"priorShares":709500},{"issuer":"TAYSHA GENE THERAPIES INC","titleOfClass":"COM SHS","cusip":"877619106","value":3825912,"shares":561808,"shareType":"SH","priorValue":1964404,"priorShares":439464},{"issuer":"AVALYN PHARMA INC","titleOfClass":"COM SHS","cusip":"05348Y105","value":3785800,"shares":115000,"shareType":"SH"},{"issuer":"AVALO THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"05338F306","value":3442972,"shares":186308,"shareType":"SH","priorValue":907863,"priorShares":60808},{"issuer":"AMYLYX PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"03237H101","value":3019345,"shares":168115,"shareType":"SH","priorValue":2099831,"priorShares":151067},{"issuer":"ARTIVA BIOTHERAPEUTICS INC","titleOfClass":"COM","cusip":"04317A107","value":2526035,"shares":260416,"shareType":"SH"},{"issuer":"COMPASS THERAPEUTICS INC","titleOfClass":"COM","cusip":"20454B104","value":1303516,"shares":595213,"shareType":"SH","priorValue":4491612,"priorShares":849076},{"issuer":"UNITED THERAPEUTICS CORP","titleOfClass":"COM","cusip":"91307C102","value":1205030,"shares":2224,"shareType":"SH","priorValue":1318788,"priorShares":2224},{"issuer":"CONTINEUM THERAPEUTICS INC-A","titleOfClass":"CL A","cusip":"21217B100","value":1034127,"shares":63095,"shareType":"SH"},{"issuer":"LB PHARMACEUTICALS INC","titleOfClass":"COM SHS","cusip":"50180M108","value":938566,"shares":28919,"shareType":"SH","priorValue":713143,"priorShares":28919}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}